Humana Inc (NYSE:HUM) announced a quarterly dividend on Friday, April 19th, Wall Street Journal reports. Stockholders of record on Friday, June 28th will be paid a dividend of 0.55 per share by the insurance provider on Friday, July 26th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Thursday, June 27th.
Humana has increased its dividend payment by an average of 18.6% per year over the last three years and has raised its dividend annually for the last 8 consecutive years. Humana has a payout ratio of 15.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Humana to earn $19.05 per share next year, which means the company should continue to be able to cover its $2.20 annual dividend with an expected future payout ratio of 11.5%.
HUM opened at $244.06 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.40. Humana has a 1-year low of $225.65 and a 1-year high of $355.88. The firm has a market capitalization of $32.93 billion, a P/E ratio of 16.77, a price-to-earnings-growth ratio of 1.00 and a beta of 0.88.
In other Humana news, insider Christopher H. Hunter sold 15,586 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $305.24, for a total value of $4,757,470.64. Following the completion of the sale, the insider now owns 28,100 shares of the company’s stock, valued at $8,577,244. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Roy A. Beveridge sold 8,278 shares of Humana stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total value of $2,542,670.48. Following the transaction, the insider now directly owns 12,409 shares in the company, valued at approximately $3,811,548.44. The disclosure for this sale can be found here. Company insiders own 0.54% of the company’s stock.
Several brokerages recently weighed in on HUM. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Oppenheimer dropped their target price on Humana from $373.00 to $350.00 and set an “outperform” rating for the company in a research report on Thursday, May 2nd. UBS Group assumed coverage on Humana in a research report on Tuesday, April 23rd. They issued a “neutral” rating and a $266.00 target price for the company. Credit Suisse Group lowered their price objective on Humana from $352.00 to $315.00 and set an “outperform” rating for the company in a research report on Thursday, May 2nd. Finally, SunTrust Banks lowered their price objective on Humana to $300.00 in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Humana presently has an average rating of “Buy” and a consensus price target of $337.26.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Percentage Gainers
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.